Investor Webinar

REACH

 

4 November 2022

 

Nuformix plc

 

("Nuformix" or the "Company" or the "Group")

 

Investor Webinar

 

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that the Company will be hosting an online presentation and Q&A session at 5.30 p.m. GMT on Wednesday 9 November 2022.  This session is open to all existing and prospective shareholders.  Those who wish to attend should register via the following link where they will be provided with access details:

 

https://us02web.zoom.us/webinar/register/WN_S2zoC1BuS8KLOVZwAhYHNQ

 

Participants will have the opportunity to submit questions during the session, but questions are welcomed in advance and may be submitted to: nuformix@investor-focus.co.uk

 

Enquiries:

 

Nuformix plc
Dr Dan Gooding, Executive Director	Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate Finance)	+44 (0) 20 3650 3650
John Howes (Corporate Broking)	+44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe Zach Cohen	+44 (0) 20 3934 6630 nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of pre-clinical assets with potential for significant value and early licensing opportunities.